173 related articles for article (PubMed ID: 36691015)
1. Clinical characteristics and outcomes of gastrointestinal stromal tumor patients receiving surgery with or without TKI therapy: a retrospective real-world study.
Wang L; Ni Z; Xu W; Mei Y; Li C; Zhu Z; Liu W
World J Surg Oncol; 2023 Jan; 21(1):21. PubMed ID: 36691015
[TBL] [Abstract][Full Text] [Related]
2. Surgical treatment and prognostic analysis for gastrointestinal stromal tumors (GISTs) of the small intestine: before the era of imatinib mesylate.
Wu TJ; Lee LY; Yeh CN; Wu PY; Chao TC; Hwang TL; Jan YY; Chen MF
BMC Gastroenterol; 2006 Oct; 6():29. PubMed ID: 17062131
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Factors After Neoadjuvant Imatinib for Newly Diagnosed Primary Gastrointestinal Stromal Tumor.
Cavnar MJ; Seier K; Gönen M; Curtin C; Balachandran VP; Tap WD; Antonescu CR; Singer S; DeMatteo RP
J Gastrointest Surg; 2021 Jul; 25(7):1828-1836. PubMed ID: 33169327
[TBL] [Abstract][Full Text] [Related]
4. [Clinical characteristics and prognosis analysis of 119 cases with giant gastrointestinal stromal tumor].
Zhang P; Zeng X; Gao J; Liu W; Shuai X; Liu K; Liu X; Cai M; Cai K; Wang G; Tao K
Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Nov; 19(11):1290-1295. PubMed ID: 27928802
[TBL] [Abstract][Full Text] [Related]
5. Cytoreductive Surgery for Metastatic Gastrointestinal Stromal Tumors Treated With Tyrosine Kinase Inhibitors: A 2-institutional Analysis.
Fairweather M; Balachandran VP; Li GZ; Bertagnolli MM; Antonescu C; Tap W; Singer S; DeMatteo RP; Raut CP
Ann Surg; 2018 Aug; 268(2):296-302. PubMed ID: 28448384
[TBL] [Abstract][Full Text] [Related]
6. [Analysis of clinical features and prognostic factors on reoperation patients with postoperative recurrence or metastasis of gastrointestinal stromal tumor].
Wang L; Xu W; Yao X; Yan C; Li C; Zhu Z; Liu W; Yan M
Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Nov; 21(11):1274-1279. PubMed ID: 30506539
[TBL] [Abstract][Full Text] [Related]
7. Gastric gastrointestinal stromal tumors: therapeutic strategies and long-term prognosis.
Shou C; Chen Z; Li Z; Yang W; Zhang Q; Bai H; Yu J
Scand J Gastroenterol; 2024; 59(2):239-245. PubMed ID: 37865826
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological features, clinical efficacy on 101 cases of rectal gastrointestinal stromal tumors, and the significance of neoadjuvant therapy.
Yang H; Shen C; Yin X; Cai Z; Wang Q; Zhang B
BMC Surg; 2021 Nov; 21(1):400. PubMed ID: 34798856
[TBL] [Abstract][Full Text] [Related]
9. Gastrointestinal Stromal Tumors: 10-Year Experience in Cancer Center-The Ottawa Hospital (TOH).
Alfagih A; AlJassim A; Alshamsan B; Alqahtani N; Asmis T
Curr Oncol; 2022 Sep; 29(10):7148-7157. PubMed ID: 36290839
[TBL] [Abstract][Full Text] [Related]
10. Clinical utility of the new American Joint Committee on Cancer staging system for gastrointestinal stromal tumors: current overall survival after primary tumor resection.
Rutkowski P; Wozniak A; Dębiec-Rychter M; Kąkol M; Dziewirski W; Zdzienicki M; Ptaszynski K; Jurkowska M; Limon J; Siedlecki JA
Cancer; 2011 Nov; 117(21):4916-24. PubMed ID: 21456019
[TBL] [Abstract][Full Text] [Related]
11. Characteristics and prognosis of jejunoileal gastrointestinal stromal tumours (GISTs) in the era of imatinib: a comparative study with gastric GISTs.
Fernández JA; Ferreras D; Ruiz-Manzanera JJ; Olivares V; Ferri B; Frutos MD; Martínez J
Clin Transl Oncol; 2021 Jul; 23(7):1368-1376. PubMed ID: 33515420
[TBL] [Abstract][Full Text] [Related]
12. Outcome of 1000 Patients With Gastrointestinal Stromal Tumor (GIST) Treated by Surgery in the Pre- and Post-imatinib Eras.
Cavnar MJ; Seier K; Curtin C; Balachandran VP; Coit DG; Yoon SS; Crago AM; Strong VE; Tap WD; Gönen M; Antonescu CR; Brennan MF; Singer S; DeMatteo RP
Ann Surg; 2021 Jan; 273(1):128-138. PubMed ID: 30946076
[TBL] [Abstract][Full Text] [Related]
13. [Analysis of gastric gastrointestinal stromal tumors in Shandong Province: a midterm report of multicenter GISSG1201 study].
Hou Q; Luo W; Li L; Dai Y; Jiang L; Wang A; Chu X; Li Y; Yang D; Lu C; Yao L; Cui G; Lin H; Chen G; Cui Q; Zhang H; Lun Z; Xia L; Su Y; Han G; Hui X; Wei Z; Sun Z; Guo H; Zhou Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):1025-1030. PubMed ID: 28900994
[TBL] [Abstract][Full Text] [Related]
14. Prognostic analysis of patients with gastrointestinal stromal tumors: a single unit experience with surgical treatment of primary disease.
Cao H; Zhang Y; Wang M; Shen DP; Sheng ZY; Ni XZ; Wu ZY; Liu Q; Shen YY; Song YY
Chin Med J (Engl); 2010 Jan; 123(2):131-6. PubMed ID: 20137358
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological and Prognostic Features of Surgical Management in Duodenal Gastrointestinal Stromal Tumors.
Shi HP; Huang ML; Wang ZQ; Zheng YN; Zhu ZL; Sah BK; Liu WT; Yan M; Zhu ZG; Li C
Dig Surg; 2018; 35(6):498-507. PubMed ID: 29232679
[TBL] [Abstract][Full Text] [Related]
16. Clinical characteristics and prognostic analysis of postoperative recurrence or metastasis of low-risk gastrointestinal stromal tumors.
Cao L; Lin C; Liu Y; Sui C; Li Z; Chen L; Guan W; Tao L; Tao T; Wang M; Wang F
World J Surg Oncol; 2024 Feb; 22(1):65. PubMed ID: 38395931
[TBL] [Abstract][Full Text] [Related]
17. [Clinicopathological features and prognosis of gastrointestinal stromal tumors with
Shen YY; Li XQ; Yang LX; Fang Y; Nie MM; He ZR; Hou YY; Cao H; Wang M; Shen KT
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Sep; 24(9):804-813. PubMed ID: 34530562
[No Abstract] [Full Text] [Related]
18. Overexpression of carbonic anhydrase II and Ki-67 proteins in prognosis of gastrointestinal stromal tumors.
Liu LC; Xu WT; Wu X; Zhao P; Lv YL; Chen L
World J Gastroenterol; 2013 Apr; 19(16):2473-80. PubMed ID: 23674848
[TBL] [Abstract][Full Text] [Related]
19. [Efficacy comparison between laparoscopy and open surgery in the treatment of gastric gastrointestinal stromal tumors larger than 2 cm using multicenter propensity score matching method].
Wu X; Sun LD; Wang M; Zhang P; Yang ZL; Liang H; Tao KX; Cao H; Xu WT
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Sep; 23(9):888-895. PubMed ID: 32927514
[No Abstract] [Full Text] [Related]
20. Is 3-years duration of adjuvant imatinib mesylate treatment sufficient for patients with high-risk gastrointestinal stromal tumor? A study based on long-term follow-up.
Lin JX; Chen QF; Zheng CH; Li P; Xie JW; Wang JB; Lu J; Chen QY; Cao LL; Lin M; Tu RH; Huang CM
J Cancer Res Clin Oncol; 2017 Apr; 143(4):727-734. PubMed ID: 28083710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
